Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.


To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Primary Outcome Measures Maximum tolerated dose [ Time Frame: up to 24 months ]A dose will be considered tolerable if there are no more than 2 out of 10 participants with dose limiting toxicities. Inclusion Criteria Age >/= 18 yearsKarnofsky performance status >/= 70%Pathologic diagnosis of malignant pleural mesothelioma at MSKPositive immunohistochemical staining for WT-1Patients must have ... [More >>]

Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis (COCOON)

Primary Outcome Measures Subjective anxiety score by using the state-trait anxiety inventory form A (STAI-Y form A) questionnaire [ Time Frame: 90 days ]State anxiety reflects the current emotional state, which allows the patient's nervousness and worry to be assessed during the session. The range is from 20 (lower anxiety) to 80 (higher anxiety). The ... [More >>]

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Primary Outcome Measures Objective response rate (ORR) [ Time Frame: 3 months-2 years ]Percentage of subjects with complete or partial response Secondary Outcome Measures duration of response (DUR) [ Time Frame: up to 2 years ]measured from first observation of response to disease progressionprogression free survival (PFS) [ Time Frame: up to 2 years ]measured from start of study to date of progression or death Other ... [More >>]

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Primary Outcome Measures The incidence and characteristics of adverse events, associated with ascending doses of Nap in combination with a set dose of durvalumab [ Time Frame: From day 1 up to 90 days following last dose of study drug ]Number of participants with infusion reactions (e.g. fever, chills, hypotension, tachycardia etc.), occurrence of any ... [More >>]

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Primary Outcome Measures Phase 1a: To assess safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD), and/or recommended dose for expansion (RDE) to Phase 1b. [ Time Frame: From the date of the first dose until 30 days after discontinuation of study treatment. ]The safety and tolerability will be based on Incidence ... [More >>]

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Primary Outcome Measures Objective Response Rate (ORR) [ Time Frame: 24 months ] Number of patients with Complete Response (CR) + Number of patients with Partial Response (PR) / total number of patients (# with CR + # with PR + # with SD + # with PD), per RECIST v1.1: CR: Disappearance of all target ... [More >>]

APG-2449 in Patients With Advanced Solid Tumors

Primary Outcome Measures Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]To determine the maximum tolerated dose (MTD) of APG-2449 in subjects with advanced solid tumorsRecommended Phase 2 dose (RP2D) [ Time Frame: 28 days ]To determine the tentative recommended Phase 2 dose (RP2D) of APG-2449 in subjects with advanced solid tumors Secondary Outcome Measures Maximum plasma concentration (Cmax) [ Time Frame: 28 ... [More >>]

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Primary Outcome Measures Phase 1 - Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ]Phase 2 - To evaluate the efficacy of autologous genetically modified TC-210 T cells in patients with MSLN-expressing unresectable, metastatic, or recurrent cancers as determined ... [More >>]

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Primary Outcome Measures Number of treatment-emergent adverse events with INCMGA00012 in combination with chemotherapy [ Time Frame: Up to approximately 27 months ]Adverse events reported for the first time or worsening of a pre-existing event after the first dose of study treatment. Secondary Outcome Measures Objective response rate (ORR) [ Time Frame: Through study completion, up to approximately 31 months ]Defined ... [More >>]

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Primary Outcome Measures Safety Profile of neoadjuvant nivolumab +/- ipilimumab in patients with resectable malignant pleural mesothelioma (MPM) with grade III/IV adverse events defined by CTCAE v5.0 [ Time Frame: up to 5 years ]Number of participants with grade III/IV adverse events defined by CTCAE v5.0, occurring within 100 days of last study drug administration ... [More >>]

Last update: May 07, 2019. 08:38:48 pm.